Author:
Linke Ebru Serinsoz,Fend Falko
Publisher
Springer International Publishing
Reference7 articles.
1. Bida, J. P., Kyle, R. A., Therneau, T. M., et al. (2009). Disease associations with monoclonal gammopathy of undetermined significance: A population-based study of 17,398 patients. Mayo Clinic Proceedings, 84, 685–693.
2. Brown, L. M., Gridley, G., Check, D., et al. (2008). Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory and allergic disorders. Blood, 111, 3388–3394.
3. Ely, S. A., & Knowles, D. M. (2002). Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol, 160, 1293–99.
4. Ely, S. A., Niesvizky, R., & Mark, T. (2014). Plasma cell neoplasms and immunoglobulin deposition diseases. In A. Orazi & K. Foucar (Eds.), Knowles neoplastic hematopathology (pp. 977–978). Philadelphia: Lippincott Williams &Wilkins.
5. International Myeloma Working Group. (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. British Journal of Haematology, 121, 749–757.